We discuss the decision-making frameworks for clinical trials with multiple co-primary endpoints in a group-sequential setting. The decision-making frameworks can account for flexibilities such as a varying number of analyses, equally or unequally spaced increments of information and fixed or adaptive Type I error allocation among endpoints. The frameworks can provide efficiency, i.e., potentially fewer trial participants, than the fixed sample size designs. We investigate the operating characteristics of the decision-making frameworks and provide guidance on constructing efficient group-sequential strategies in clinical trials with multiple co-primary endpoints.
The resulting need for new approaches to the design and analysis of clinical trials with co-primary endpoints has been noted . Specifically controlling the Type I and Type II error rates when multiple co-primary endpoints are potentially correlated is non-trivial. In hypothesis testing for the co-primary endpoints, the null hypothesis is rejected if and only if all of the null hypotheses associated with each of the endpoints are rejected at a significance level of . No adjustment is needed to control the Type I error rate if each endpoint is tested at the same prespecified significance level. The corresponding rejection region of the null hypothesis, defined as the intersection of regions associated with the co-primary endpoints is considerable restricted and thus the hypothesis testing is conservative, especially when the number of endpoints to be evaluated is large. On the other hand, when designing the trial with co-primary endpoints, the overall power should be maintained to evaluate the joint effects on all of the endpoints. Since the Type II error rate increases as the number of endpoints increases, this requires the sample size adjustment and may often result in a sample size that is too large and impractical to conduct the clinical trial.
In order to provide a more reasonable and practical sample size, methods for clinical trials with co-primary endpoints have been discussed in fixed sample size designs by many authors Hamasaki et al., 2013; Julious and Mclntyre, 2012; Kordzakhia et al., 2010; Offen et al, 2007; Senn and Bretz, 2007; Sozu et al., 2010 Sozu et al., , 2011 Sozu et al., , 2012 Sozu et al., , 2015 Sugimoto et al., 2012 Sugimoto et al., , 2013 Xiong et al., 2005) . These methods commonly consider incorporating the correlations among the endpoints into the sample size calculation. Hung and Wang (2009) discussed group-sequential strategies for clinical trials with multiple primary endpoints. These strategies provide the possibility of stopping a trial early when evidence is overwhelming, thus offering efficiency (i.e., potentially fewer patients than the fixed sample size designs). The methods also allow recalculation of the sample size based on the observed interim effects sizes. Recently Asakura et al. (2014 Asakura et al. ( , 2015 discuss two decision-making frameworks associated with hypothesis testing in clinical trials with two continuous or binary endpoints as co-primary in a group-sequential setting. One framework is to reject the null hypothesis if and only if statistical significance is achieved for the two endpoints simultaneously (i.e., at the same interim timepoint of the trial). The other is a generalization of this, i.e., to reject the null hypothesis if superiority is demonstrated for the two endpoints at any interim timepoint (i.e., not necessarily simultaneously). The former framework is independently discussed by Chang et al. (2014) and evaluated in clinical trials with two co-primary endpoints. In the latter decision-making framework, Asakura et al. (2014 Asakura et al. ( , 2015 assume that the same number of analyses with a common information level between the two endpoints, and the Type I error allocation to each interim look should be specified and determined in advance, using any alpha-spending function method. However, the latter decision-making framework can be further generalized to accommodate a varying number of analyses and equally or unequally spaced increments of information among the endpoints.
In the decision-making framework above, the maximum Type I error rate associated with the rejection region of the null hypothesis for co-primary endpoints is not inflated over the prespecified significance level. However, the rejection region of the null hypothesis is still restricted similarly as in the fixed sample size designs, because there is a requirement that the allocation of Type I error to each interim analysis for all of the endpoints, be prespecified. To relax the rejection region of the null hypothesis for co-primary endpoints, the decisionmaking framework can be modified to allocate adaptively the Type I error to each interim look, using the methodology of hierarchical hypothesis testing with the adaptive Type I error allocation discussed in Tsong et al. (2004) . However, Hung et al. (2007) cautions on the Type I error inflation in hierarchical hypothesis testing for detecting an effect on at least one endpoint in a group-sequential setting with multiple primary endpoints, and thus we need to investigate carefully how the Type I error rate behaves when using hierarchical hypothesis testing with the adaptive Type I error allocation in a group-sequential setting with multiple co-primary endpoints.
The flexibilities and extensions mentioned above may improve the power and rejection region of the tests, providing efficiency. However the decision-making and operational issues associated with the trial will be more complex and challenging. The objective of the paper is to investigate the operating characteristics (overall power, Type I error, and sample size) of the three decision-making frameworks for group-sequential strategies in clinical trials with multiple co-primary endpoints. The first two frameworks are the extensions of works in Asakura et al (2014) and Cheng et al (2014) to multiple co-primary endpoints when appropriately planning for a potentially varying number of analyses and information levels with the prespecified and fixed Type I error allocation. The last framework is an extension of the work in Tsong (2004) to multiple co-primary endpoints with adaptive Type I error allocation. We discuss the fundamental features of the three frameworks. We will not discuss methods for adaptation based on effects observed at interim of a trial. For sample size recalculation based on the conditional power, please see Asakura et al. (2014) and Cheng et al (2014) . Asakura et al (2014) have extensively discussed and evaluated the sample size recalculation based on the conditional power with Cui-Hung-Wang statistics (Cui et al., 1999) . This paper is structured as follows: in Section 2 we outline the decision-making frameworks for group-sequential strategies in clinical trials with multiple co-primary endpoints and briefly describe the power and sample size calculations in Section 3. In Section 4, we evaluate the operating characteristics of the three decision-making frameworks including power, Type I error rate and sample sizes. We summarize the findings and discuss advantages and disadvantages of the three decision-making frameworks in Section 5.
2 Group-sequential designs with co-primary endpoints 
Statistical Settings

Decision-making framework A: Prespecified and fixed Type I error allocation
When evaluating the joint effects on all endpoints within the context of group-sequential designs, a general decision-making framework associated with hypothesis testing is to reject H if statistical significance of a test intervention relative to control is achieved for all endpoints at any interim timepoint until the final analysis (i.e., not necessarily simultaneously) (DF-A). If superiority is demonstrated on some but not all of the endpoints at the interim, then the trial will continue but subsequent hypothesis testing is repeatedly conducted only for the previously non-significant endpoint(s). Thus DF-A offers the opportunity of stopping measurement of an endpoint for which superiority has already been demonstrated. Stopping measurement may be desirable if the endpoint is very invasive or expensive (e.g., data from a liver biopsy or gastro-fiberscope, or data from expensive imaging). In addition, DF-A is a flexible strategy that allows the option of selecting different timings for interim looks among the endpoints. For example, when two endpoints are considered as co-primary and the number of analyses is four for one endpoint and three for the other endpoint, DF-A can allow for information times of 0.25, 0.50, 0.75 and 1.0 for one endpoint and 0.33, 0.67 and 1.0 for the other endpoint. However, the different timings for interim looks may create operational difficulty in conducting a clinical trial. For practical purposes, in Section 4, we will consider a situation where the timing of interim looks is the same among the endpoints, e.g., 0.25, 0.50, 0.75 and 1.0 for one endpoint and 0.50, 0.75 and 1.0 for the other endpoint.
Here suppose that analyses are planned for each endpoint and a total number of analyses is the sum of the number of analyses over all of the endpoints excluding the duplications of the same information time ⁄ ⁄ . The stopping rule for DF-A is formally given as follows: Therefore, the overall power corresponding to DF-A' is a special case of DF-A,
DF-A' is simpler but less powerful than DF-A. This will be illustrated in Section 4.
Decision-making framework B: Hierarchical hypothesis testing with adaptive Type I error allocation
For the methods discussed in the previous section, the rejection region of the null hypothesis is still restricted, as with the fixed sample size designs, because the allocation of Type I error to each interim analysis for all endpoints should be prespecified using an alpha-spending method. To overcome the issue, the decision-making framework can be modified to allocate adaptively the Type I error to each interim look, using the methodology of hierarchical hypothesis testing with adaptive Type I error allocation. This idea is discussed by Tsong et al.
(2004) in group-sequential three-arm clinical trials when assessing the equivalence and efficacy of a generic product, where the co-primary objectives of the study are to assess whether the generic and reference product are effective relative to placebo and whether the generic is equivalent to the reference product with a prespecified equivalence margin. Their method evaluates equivalence only after both null hypotheses of efficacy are rejected and then to specify the Type I error allocation before the equivalence evaluation is performed.
When extending the hierarchical hypothesis testing with adaptive Type I error allocation to clinical trials with multiple endpoints as co-primary, the order of the hypothesis testing for each endpoint is determined even when the endpoints are equally important and the Type I error allocation for the first-tested endpoint is prespecified, using an alpha spending method, where a maximum of planned analyses for the first-tested endpoint is . If superiority is established for the first-tested endpoint at th analysis with information time ⁄ ( 0 1), then the Type I error allocation for the second-tested endpoint is specified before the hypothesis testing for the second-tested endpoint is performed, where a maximum of planned analyses for the second-tested endpoint is . If superiority has been established for the second-tested endpoint at th analysis with information time ⁄
( 1), then the Type I error allocation for the third-tested endpoint is specified before the hypothesis testing for the third-tested endpoint is performed. These steps are repeated for th-tested endpoint until H is rejected. The stopping rule for DF-B is formally given as follows:
For th-tested endpoint (1 ), at the th analysis ( 1, … , 1), For example, consider a clinical trial with two co-primary endpoints, where the maximum number of analyses for the first-tested endpoint is 5, with equally spaced increments of information and the O'Brien-Fleming-type boundary is used to reject the null hypothesis for the first-tested endpoint with the significance level of 2.5% for a one-sided test. The second-tested endpoint is evaluated only after the null hypothesis for the first-tested endpoint is rejected. The second endpoint is tested at the remaining planned analyses for the first-tested endpoint, and the O'Brien-Fleming-type boundary (O'Brien and Fleming, 1979 ) is used to reject the null hypothesis for the second-tested endpoint with the significance level of 2.5% for a one-sided test, as shown in Table 1 . If the first-tested endpoint is statistically significant at the 4th look, then the second-tested endpoint is tested twice with the boundary of 2.2504 at 4th analysis and 2.0249 at the final analysis.
The overall power for DF-B is
For the sample size calculation, the number of interim analyses and the information time for all of the endpoints should be prespecified. As mentioned in Section 1, Hung et al. (2007) discuss the behavior of the Type I error rate when hierarchical hypothesis testing is used for detecting an effect on at least one endpoint in a group-sequential setting and caution that the conventional hierarchical testing strategy may violate the closed testing principle and thus the overall Type I error rate may not be controlled in the strong sense. They show that, when considering the two endpoints as primary and testing the two hypotheses for the two endpoints with the hierarchical order, the Type I error rate for the second endpoint is inflated over the prespecified significance level, depending on the effect size for the first endpoint and correlation between the endpoint. Thus DF-B may not control the Type I error rate adequately.
This will be further evaluated in Section 4 and the Appendix.
Calculation for power and sample sizes
The powers (1), (2) and (3) defined in the previous sections can be evaluated using the numerical integration method in Genz (1992) or other methods. The power calculation requires considerable computing time and memory especially with a large number of endpoints or number of analyses. The accuracy of the computation should be carefully controlled as it is sensitive to the number of endpoints and the number of analyses.
We describe two sample size concepts, i.e., the maximum sample size (MSS) and the average sample number (ASN) (i.e., expected sample size) based on the power (1), (2) or (3).
The MSS is the sample size required for the final analysis to achieve the desired power 1 .
The MSS is given by the smallest integer not less than satisfying the power for a groupsequential strategy at the prespecified and , with Fisher's information time for the interim analyses, ⁄ ( 1, … , ). To identify the value of , an easy strategy is a grid search to gradually increase (or disease) until the power under exceeds (or falls below) the desired power. As seen in Appendix 1, the grid search often requires considerable computing time, especially with a larger number of endpoints, a larger number of analyses, or a small effect size. To reduce the computing time, the Newton-Raphson algorithm in Sugimoto et al. (2012) or the basic linear interpolation algorithm in Hamasaki et al. (2013) may be utilized. In this paper, we use of the basic linear interpolation algorithm to reduce the computing time.
The ASN is the expected sample size under hypothetical reference values and provides information regarding the number of participants anticipated in a group-sequential design in order to reach a decision point, and the ASN per intervention group is given by
where , … , is stopping probability (or exit probability) as defined the likelihood of crossing the critical boundaries at the th interim look assuming the true values of the intervention's effect are , … , .
Both MSS and ASN depend on the design parameters including differences in means, the correlation structure among the endpoints, the selected stopping boundary based on LD alpha-spending method (e.g., O'Brien-Fleming-type boundary, Pocock-type boundary (Pocock, 1977) ), the number of analyses, and equally or unequally spaced increments of information.
Our experience suggests that, as shown in Appendix, when considering more than two endpoints as co-primary in a group-sequential setting with more than five analyses, calculating the multivariate normal integrals often requires considerable computing time. A Monte-Carlo simulation-based method provides an alternative but the number of replications for simulations should be carefully chosen to control simulation error in calculating the empirical power.
Operating characteristics of the decision-making frameworks in groupsequential strategies
In this section, we investigate the operating characteristics of the decision-making frameworks for the group-sequential strategies described in the previous section including the overall Type I error rate, overall power and ASN under a given sample size, of one-sided test.
and For illustration, we consider a simple situation, i.e., a randomized clinical trial designed to compare a test intervention to a control intervention with two outcomes being evaluated as co-primary endpoints. We evaluate the operating characteristics of the decision-making frameworks for group-sequential strategies shown in Tables 2 and 3. They include clinical trials with a maximum number of analyses of 2 or 5, and equally spaced increments of information for one endpoint, but unequally spaced increments for other endpoint, with a common variance 1.0. One-sided statistical testing is conducted at the significance level of α 2.5%. A range of correlation between the two outcomes considered in the evaluation is , 0 since the correlation among the endpoints are usually nonnagetive as discussed in Often et al (2007) . The overall power and Type I error rate is evaluated using the numerical integration method in Genz (1992) . However, the accuracy of the computation for the overall power and Type I error rate may depend on the number of analyses. Therefore, Monte-Carlo simulation was also performed to confirm the result from the numerical integration method. A total of 100,000 replications and 1,000,000 replications are selected for the assessments of power and Type I error rate respectively. The number of replications was determined based on the precision, where a sample size of 1,000,000 provides a two-sided 95% confidence interval with a width equal to 0.001 when the proportion is 0.025, and 100,000 replications provides a two-sided 95% confidence interval with a width equal to 0.005 when the proportion is 0.80. The results presented in this manuscript were by the numerical integration methods, but the Monte-Carlo simulation confirmed these results.
Behaviors of the overall Type I error rate
Figures 1 ( 2) and 2 ( 5) illustrate the behaviors of the Type I error rate with correlation under a given sample size per group (equally-sized groups: 1) in the decision-making frameworks for group-sequential strategies with two co-primary endpoints as shown in Tables   2 and 3 combinations. The smallest ASN is given by Strategy #2 (DF-B) and the largest ASN is given by Strategy #6 (DF-A). In summary, delaying the analysis for one of the endpoints increases the power but increases ASN.
Behaviors of the overall power and ASN
Summary and discussion
The determination of sample size and the evaluation of power are fundamental and critical elements in the design of a clinical trial. If a sample size is too small then important effects may not be detected, while a sample size that is too large is wasteful of resources and unethically puts more participants at risk than necessary. Recently many clinical trials have been designed with more than one endpoint considered as primary. When utilizing multiple endpoints in clinical trials, we must distinguish between the two inferential goals of clinical trials based on multiple endpoints, i.e., a decision must be made as to whether it is desirable to evaluate the joint effects on all endpoints or at least one of the endpoints. The former is referred as to "multiple co-primary endpoints" and the latter as to "multiple primary endpoints" . In this paper, we discuss methods for multiple co-primary endpoints. Coprimary endpoints offer an attractive design feature as they capture a more complete characterization of the effect of an intervention. However co-primary endpoints create challenges in the evaluation of power and the calculation of sample size during trial design as the power is decreased and the sample size is increased with the larger number of endpoints.
Currently utilized methods often result in large and impractical sample sizes.
In this paper, as an extension of the work in Asakura et al. (2014 Asakura et al. ( , 2015 , we consider three decision-making frameworks for group-sequential strategies with multiple co-primary endpoints when appropriately planning for a varying number of analyses for each endpoint and equally or unequally spaced increments of information when the trial is designed to evaluate if a new intervention is superior to a control on all of the endpoints. We also consider the use of hierarchical hypothesis testing methodology with the adaptive Type I error allocation, which was discussed by Tsong et al. (2004) . Then we investigate the operating characteristics of group-sequential strategies for clinical trials with multiple co-primary endpoints. Based on the investigations, our findings are summarized in Table 4 .
The decision-making framework using hierarchical hypothesis testing with adaptive Type I error allocation (DF-B) has the attractive features of providing higher power and smaller sample sizes compared with the decision-making frameworks with prespecified and fixed Type I error allocation (DF-A or DF-A'). However, the Type I error rate is inflated and depends on the correlation, effect sizes, and the stopping boundary. As seen in clinical trials with two co-primary endpoints, the correlation between the endpoints and the effect size of the first-tested endpoint are the nuisance parameters that determine the stopping boundary and then the level of the Type I error. In practice, use of DF-B should be carefully considered. In a similar but not identical setting, i.e., at least one endpoint with one interim analysis, and one primary and one secondary endpoints, the behavior of the Type I error for hierarchical hypothesis testing has been well-studied (Glimm et al, 2010; Hung et al, 2007; Tamhane et al, 2010) . By the analogy between these studies and the investigation given in Appendix 2, one simple solution is to test the hypothesis for the second-tested endpoint only once although further investigation will be required to evaluate more general situations with more than two analyses.
The decision-making framework with prespecified and fixed Type I error allocation (DF-A or DF-A') can adequately control the Type I error rate. They are less powerful than DF-B, but differences in power and required sample sizes are very modest. Especially, when the O'Brien-Fleming-type boundary is selected for both endpoints, there is little difference in power, maximum sample size, and average sample number. DF-A provides the flexibility of selecting differently spaced information levels and different numbers of analyses among the endpoints. In some clinical trials, information for the endpoints may not accrue at the same rate. For example, progression-free survival and overall survival are common endpoints in oncology trials and require different information times. DF-A is useful when designing clinical trials with such endpoints. Strategic selection regarding the number of analyses with equally or unequally spaced information level among the endpoints may improve the power and reduce the sample sizes. However, when selecting a different number of analyses among the endpoints, early interim evaluations should be carefully evaluated as they can provide higher power but larger average sample numbers. DF-A also offer the option of stopping measurement of an endpoint for which superiority has been demonstrated. This may be desirable if the endpoint is very invasive or expensive. However, these complexities may raise operational challenges. Stopping measurement after interim analysis can raise a major concern about study integrity and can affect the validity of the statistical conclusions reached for a clinical trial. In practice, we should carefully consider how to minimize this risk.
When constructing efficient group-sequential strategies in clinical trials with multiple coprimary endpoints, there are two practical questions. The first question is the choice of the stopping boundary based on an alpha-spending function for each endpoint. If the trial was designed to detect effects on at least one endpoint with a prespecified ordering of endpoints, then the selection of different boundaries for each endpoint (i.e., the O'Brien-Fleming-type for the primary endpoint and the Pocock-type boundary for the secondary endpoint) can provide a higher power than using the same boundary for both endpoints (Glimm et al., 2010; Tamhane et al., 2010) . However, as shown in Section 4, the selection of a different boundary has a minimal effect on the overall power and average sample number. In all of the three decision-making frameworks, regardless of equal or unequal effect sizes among the endpoints, the largest power is obtained from the O'Brian-Fleming-type boundary for all of the endpoints, and the lowest is the Pocock-type boundary for all of the endpoints. Regarding the average sample number, the smallest is provided by the Pocock-type boundary for all of the endpoints, the largest is provided by the O'Brian-Fleming-type boundary. One possible scenario for selecting a different boundary is when one endpoint is invasive and stopping to measurement of the endpoint is desirable as soon as possible, i.e., once the superiority for the endpoint has been demonstrated. Table 5 illustrates the expected number of observations per intervention group for each endpoint based on the decision-making frameworks DF-A under a given maximum sample size in clinical trials with two co-primary endpoints, EP1 and EP2. 
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